Should I buy or sell Karuna Therapeutics stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karuna Therapeutics in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" KRTX shares. View KRTX analyst ratings or view top-rated stocks .

What is Karuna Therapeutics' stock price target for 2024?

12 Wall Street analysts have issued 1-year price targets for Karuna Therapeutics' shares. Their KRTX share price targets range from $209.00 to $318.00. On average, they expect the company's share price to reach $259.38 in the next twelve months. This suggests a possible upside of 39.5% from the stock's current price. View analysts price targets for KRTX or view top-rated stocks among Wall Street analysts .

How have KRTX shares performed in 2023?

Karuna Therapeutics' stock was trading at $196.50 at the start of the year. Since then, KRTX stock has decreased by 5.4% and is now trading at $185.91. View the best growth stocks for 2023 here .

When is Karuna Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024. View our KRTX earnings forecast .

How were Karuna Therapeutics' earnings last quarter?

Karuna Therapeutics, Inc. (NASDAQ:KRTX) released its quarterly earnings data on Thursday, November, 2nd. The company reported ($3.16) EPS for the quarter, missing analysts' consensus estimates of ($2.74) by $0.42. Karuna Therapeutics had a negative trailing twelve-month return on equity of 29.58% and a negative net margin of 2,795.96%.

What ETFs hold Karuna Therapeutics' stock?

ETFs with the largest weight of Karuna Therapeutics (NASDAQ:KRTX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN) , Invesco Dorsey Wright Healthcare Momentum ETF (PTH) , Alpha Architect U.S. Quantitative Momentum ETF (QMOM) , Principal Healthcare Innovators ETF (BTEC) , SPDR S&P Biotech ETF (XBI) , Direxion Daily S&P Biotech Bull 3x Shares (LABU) , Invesco Nasdaq Biotechnology ETF (IBBQ) and Vanguard Russell 2000 Growth ETF (VTWG) .

What other stocks do shareholders of Karuna Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karuna Therapeutics investors own include NVIDIA (NVDA) , Micron Technology (MU) , Advanced Micro Devices (AMD) , AbbVie (ABBV) , Pfizer (PFE) , Alibaba Group (BABA) , Johnson & Johnson (JNJ) , AT&T (T) , Target (TGT) and Walt Disney (DIS) .

When did Karuna Therapeutics IPO?

(KRTX) raised $70 million in an IPO on Friday, June 28th 2019. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Karuna Therapeutics' major shareholders?

Karuna Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (14.98%), Pivotal bioVenture Partners Investment Advisor LLC (2.11%), Rock Springs Capital Management LP (1.34%), Invesco Ltd. (0.97%), Eventide Asset Management LLC (0.90%) and Brown Advisory Inc. (0.86%). Insiders that own company stock include Andrew Craig Miller , Atul Pande , James Healy , Jeffrey M Jonas , Laurie J Olson, Laurie J Olson , Puretech Health Llc, Stephen K Brannan , Steven M Paul and Troy A Ignelzi . View institutional ownership trends .

How do I buy shares of Karuna Therapeutics?

Shares of KRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Karuna Therapeutics Stock Price, News & Analysis (NASDAQ:KRTX)

$189.48

+4.13 (+2.23%)

(As of 02:23 PM ET)

Compare

Today's Range: $185.84
▼
$193.57
50-Day Range: $161.01
▼
$190.94
52-Week Range: $158.38
▼
$245.00

Volume: 116,879 shs
Average Volume: 329,602 shs
Market Capitalization: $7.15 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $259.38

Karuna Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.83 Rating Score
Upside/Downside: 39.5% Upside
$259.38 Price Target
Short Interest: Bearish
5.06% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.94
Based on 5 Articles This Week
Insider Trading: Selling Shares
$5.27 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($11.31) to ($11.25) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

494th out of 949 stocks

Pharmaceutical Preparations Industry

231st out of 437 stocks

4.4

Analyst's Opinion

Consensus Rating
Karuna Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 10 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $259.38, Karuna Therapeutics has a forecasted upside of 39.5% from its current price of $185.91.
Amount of Analyst Coverage
Karuna Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
5.06% of the outstanding shares of Karuna Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Karuna Therapeutics has a short interest ratio ("days to cover") of 8.1.
Change versus previous month
Short interest in Karuna Therapeutics has recently increased by 3.80%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Karuna Therapeutics does not currently pay a dividend.
Dividend Growth
Karuna Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for KRTX.

3.3

News and Social Media Coverage

News Sentiment
Karuna Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.74 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Karuna Therapeutics this week, compared to 4 articles on an average week.
MarketBeat Follows
1 people have added Karuna Therapeutics to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Karuna Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,270,775.00 in company stock.
Percentage Held by Insiders
13.20% of the stock of Karuna Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Karuna Therapeutics are expected to grow in the coming year, from ($11.31) to ($11.25) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Karuna Therapeutics is -17.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Karuna Therapeutics is -17.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Karuna Therapeutics has a P/B Ratio of 5.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Karuna Therapeutics Stock (NASDAQ:KRTX)

Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate includes KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of various peripheral tissues and dementia-related psychosis, including Alzheimer's disease. The company also focuses on developing other muscarinic-targeted drug candidates; and intends to develop lead candidature TRPC4/5 and KAR-2618 for the treatment of mood and anxiety disorders. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company, and Zai Lab (Shanghai) Co., Ltd; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics, Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

KRTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

KRTX Stock News Headlines

November 29, 2023 | msn.com

FDA accepts Karuna Therapeutics schizophrenia drug for review

November 29, 2023 | markets.businessinsider.com

FDA Accepts New Drug Application For Karuna Therapeutics' KarXT To Treat Schizophrenia

November 29, 2023 | Tomorrow Investor (Ad)

The Only Practical Solution to the World’s Looming Energy Crisis

There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!

November 29, 2023 | finance.yahoo.com

Karuna Therapeutics Announces U.S. Food and Drug Administration Accepts New Drug Application for KarXT for the Treatment of Schizophrenia

November 24, 2023 | benzinga.com

Karuna Therapeutics Stock (NASDAQ:KRTX) Dividends: History, Yield and Dates

November 21, 2023 | americanbankingnews.com

Karuna Therapeutics' (KRTX) Buy Rating Reaffirmed at HC Wainwright

November 21, 2023 | markets.businessinsider.com

Positive Phase 1b Trial Results Bolster Buy Rating for Karuna Therapeutics: Potential for Rapid Market Adoption of KarXT

November 21, 2023 | markets.businessinsider.com

Karuna Therapeutics Stock Receives Buy Rating Following Successful Phase 1b ABPM Study Results of KarXT

November 29, 2023 | Tomorrow Investor (Ad)

The Only Practical Solution to the World’s Looming Energy Crisis

There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!

November 19, 2023 | americanbankingnews.com

Karuna Therapeutics (NASDAQ:KRTX) Trading 5.7% Higher

November 19, 2023 | americanbankingnews.com

Karuna Therapeutics (NASDAQ:KRTX) Stock Rating Reaffirmed by Wedbush

November 19, 2023 | americanbankingnews.com

Karuna Therapeutics (NASDAQ:KRTX) Rating Reiterated by JMP Securities

November 17, 2023 | msn.com

Karuna Therapeutics Says Its Antipsychotic Candidate Shows Favorable Cardiovascular Safety Profile In Schizophrenia Patients

November 17, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Notable Labs (NTBL), Karuna Therapeutics (KRTX)

November 17, 2023 | markets.businessinsider.com

Analyst Endorses Karuna Therapeutics’ KarXT Following Positive Safety Trial Results and Anticipates High Market Potential

November 17, 2023 | finance.yahoo.com

Karuna (KRTX) Posts Upbeat Safety Data on Schizophrenia Drug

November 16, 2023 | msn.com

Karuna reports positive safety data for schizophrenia drug KarXT

November 16, 2023 | finance.yahoo.com

Karuna Therapeutics Announces Positive Results from Phase 1b Ambulatory Blood Pressure Monitoring Trial of KarXT in Schizophrenia

November 6, 2023 | markets.businessinsider.com

Karuna Therapeutics Earns ‘Buy’ Rating: Strong Clinical Progress and Robust Financial Position Bolster Confidence

November 6, 2023 | finance.yahoo.com

Karuna Therapeutics, Inc. (NASDAQ:KRTX) Q3 2023 Earnings Call Transcript

November 6, 2023 | seekingalpha.com

Karuna Therapeutics: Rewiring The Schizophrenia Paradigm - A Novel Leap Beyond Dopamine

November 5, 2023 | seekingalpha.com

Karuna Therapeutics, Inc. (KRTX) Q3 2023 Earnings Conference Call Transcript

November 4, 2023 | markets.businessinsider.com

Buy Rating for Karuna Therapeutics: Promising Outlook Based on KarXT’s Potential and Ongoing Clinical Programs

November 3, 2023 | finance.yahoo.com

Karuna's (KRTX) Q3 Loss Wider-Than-Expected, Sales Miss

November 3, 2023 | finance.yahoo.com

Q3 2023 Karuna Therapeutics Inc Earnings Call

November 2, 2023 | finance.yahoo.com

Karuna Therapeutics Inc (KRTX) Reports Q3 2023 Financial Results and Business Updates

November 2, 2023 | finance.yahoo.com

Karuna Therapeutics Reports Third Quarter 2023 Financial Results and Provides General Business Updates

See More Headlines

Receive KRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Karuna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/02/2023
Today: 11/29/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/22/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:KRTX
CUSIP: N/A
CIK: 1771917
Web: karunatx.com
Phone: (857) 449-2244
Fax: N/A
Employees: 210
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $259.38
High Stock Price Target: $318.00
Low Stock Price Target: $209.00
Potential Upside/Downside: +36.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.83
Research Coverage: 12 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($10.93)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-276,340,000.00
Net Margins: -2,795.96%
Pretax Margin: -6,661.80%
Return on Equity: -29.58%
Return on Assets: -28.61%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 27.88
Quick Ratio: 27.88

Sales & Book Value

Annual Sales: $10.64 million
Price / Sales: 676.41
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $35.05 per share
Price / Book: 5.44

Miscellaneous

Outstanding Shares: 37,730,000
Free Float: 32,747,000
Market Cap: $7.20 billion
Optionable: Not Optionable
Beta: 1.14

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Dr. Andrew Craig Miller (Age 41)
Co-Founder & COO
Comp: $835.4k
Dr. Steven M. Paul M.D. (Age 72)
President of Research and Development, Chief Scientific Officer & Director
Comp: $1.32M
Dr. Stephen K. Brannan (Age 67)
Chief Medical Officer
Comp: $751.75k
Mr. William Meury (Age 55)
President, CEO & Director
Mr. Jason Parker Brown
Chief Financial Officer
Ms. Alexis Smith
Vice President of Corporate Affairs & Investor Relations
Ms. Mia Kelley J.D.
Vice President of Legal Affairs
Mr. Frank Truslow
Senior Vice President of Corporate Development
Mr. Jonathan Rosin
Chief Human Resources Officer
Dr. Alan Breier
Chair of Scientific Advisory Board & Chief Clinical Advisor

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KRTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Karuna Therapeutics stock right now?: 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karuna Therapeutics in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" KRTX shares.
View KRTX analyst ratings or view top-rated stocks.
What is Karuna Therapeutics' stock price target for 2024?: 12 Wall Street analysts have issued 1-year price targets for Karuna Therapeutics' shares. Their KRTX share price targets range from $209.00 to $318.00. On average, they expect the company's share price to reach $259.38 in the next twelve months. This suggests a possible upside of 39.5% from the stock's current price.
View analysts price targets for KRTX or view top-rated stocks among Wall Street analysts.
How have KRTX shares performed in 2023?: Karuna Therapeutics' stock was trading at $196.50 at the start of the year. Since then, KRTX stock has decreased by 5.4% and is now trading at $185.91.
View the best growth stocks for 2023 here.
When is Karuna Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, February 22nd 2024.
View our KRTX earnings forecast.
How were Karuna Therapeutics' earnings last quarter?: Karuna Therapeutics, Inc. (NASDAQ:KRTX) released its quarterly earnings data on Thursday, November, 2nd. The company reported ($3.16) EPS for the quarter, missing analysts' consensus estimates of ($2.74) by $0.42. Karuna Therapeutics had a negative trailing twelve-month return on equity of 29.58% and a negative net margin of 2,795.96%.
What ETFs hold Karuna Therapeutics' stock?: ETFs with the largest weight of Karuna Therapeutics (NASDAQ:KRTX) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), Alpha Architect U.S. Quantitative Momentum ETF (QMOM), Principal Healthcare Innovators ETF (BTEC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Biotechnology ETF (IBBQ) and Vanguard Russell 2000 Growth ETF (VTWG).

What other stocks do shareholders of Karuna Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Karuna Therapeutics investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), AbbVie (ABBV), Pfizer (PFE), Alibaba Group (BABA), Johnson & Johnson (JNJ), AT&T (T), Target (TGT) and Walt Disney (DIS).
When did Karuna Therapeutics IPO?: (KRTX) raised $70 million in an IPO on Friday, June 28th 2019. The company issued 4,400,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Citigroup and Wells Fargo Securities served as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Who are Karuna Therapeutics' major shareholders?: Karuna Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (14.98%), Pivotal bioVenture Partners Investment Advisor LLC (2.11%), Rock Springs Capital Management LP (1.34%), Invesco Ltd. (0.97%), Eventide Asset Management LLC (0.90%) and Brown Advisory Inc. (0.86%). Insiders that own company stock include Andrew Craig Miller, Atul Pande, James Healy, Jeffrey M Jonas, Laurie J Olson, Laurie J Olson, Puretech Health Llc, Stephen K Brannan, Steven M Paul and Troy A Ignelzi.
View institutional ownership trends.
How do I buy shares of Karuna Therapeutics?: Shares of KRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:KRTX) was last updated on 11/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Karuna Therapeutics Stock Price, News & Analysis (NASDAQ:KRTX)

Karuna Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Karuna Therapeutics Stock (NASDAQ:KRTX)

KRTX Stock Price History

KRTX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

KRTX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™